TELA Bio (TELA) Investor Presentation - Slideshow

Market Opportunity - TELA Bio addresses a ~$2 billion U S market opportunity in soft tissue reconstruction[4] - The annual U S total addressable hernia market opportunity for OviTex is approximately $1.5 billion[5,6] - Plastic and reconstructive surgery represents an approximate $500 million annual U S market opportunity[41] Product & Technology - TELA Bio markets a new category of tissue reinforcement materials for soft tissue reconstruction[4] - OviTex products are designed with over 95% biologic material and less than 5% polymer/synthetic content[24] - OviTex LPR is tailored for robotic-assisted hernia surgical repairs, with 4 total SKUs available after commercial introduction of 3 additional SKUs in December 2019[32] Clinical Evidence - The BRAVO study showed a 0% hernia recurrence rate in the first 20 patients at 24 months and a 2% hernia recurrence rate in the first 57 patients at 12 months[34,38] - Post-market clinical studies of competitive materials show hernia recurrence rates of 5% to 23% for resorbable synthetic mesh (Phasix) at 12 to 36 months, and 22% to 33% for biologic matrix (Strattice) at 12 to 24 months[38] Financial Performance - Q2 2020 revenue increased 6% over the prior year period[57] - As of June 30, 2020, total cash and cash equivalents were $85.5 million[57]